Regulatory approval

Published by the European Medicines Agency. Approved

Perjeta is indicated for use in combination with trastuzumab and chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence.

This is written in the approval document.

Citation

Roche Registration GmbH. Perjeta (pertuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf. Revised December 2021. Accessed March 22, 2024.

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations
Biomarkers
Cancer types
Therapies
Organizations Biomarkers Cancer types Therapies
EMA (1) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Doxorubicin, Fluorouracil, Pertuzumab, Trastuzumab
EMA (1) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Doxorubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab
EMA (1) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Epirubicin, Pertuzumab, Trastuzumab
EMA (1) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Epirubicin, Paclitaxel, Pertuzumab, Trastuzumab
EMA (1) HER2-positive Invasive Breast Carcinoma Carboplatin, Docetaxel, Pertuzumab, Trastuzumab

Contributions

Date Contributor Description
2024-10-20 Van Allen lab Adding EMA approvals for use to database
2018-05-31 European Medicines Agency Indication received approval from the European Commission.